Providers Clinical Support System Substance Use Disorder Treatment (PCSS-SUD Treatment)

The Providers Clinical Support System – Substance Use Disorder Treatment (PCSS-SUD Treatment) grant, issued under opportunity number TI-26-002, is a federal initiative by the U.S. Department of Health and Human Services, specifically through the Substance Abuse and Mental Health Services Administration (SAMHSA). This program is forecasted for fiscal year 2026 and falls under the discretionary funding category. It is part of the broader CFDA program 93.243, which focuses on Substance Abuse and Mental Health Services Projects of Regional and National Significance. The PCSS-SUD Treatment program is expected to offer a cooperative agreement as its funding instrument and aligns with SAMHSA’s ongoing mission to improve substance use disorder (SUD) treatment capacity in the United States. The core purpose of the PCSS-SUD Treatment grant is to provide comprehensive training, technical assistance (TTA), mentoring, and sustained support for healthcare and counseling professionals. The program targets practitioners in general health and behavioral health settings to enhance their capabilities in identifying and treating substance use disorders. Through this intervention, SAMHSA aims to boost the number of general and specialized healthcare providers who can effectively offer SUD services. The ultimate goal is to increase access to evidence-based treatment options for individuals dealing with substance use disorders, thus mitigating the public health burden associated with untreated addiction. While detailed information on funding mechanisms and restrictions is not yet available due to the opportunity’s forecasted status, the total anticipated program funding is $3,000,000. There is no cost-sharing or matching requirement associated with this grant, which may encourage a wider range of applicants to participate. The grant is expected to fund one awardee, though specifics regarding award ceilings, floors, and performance periods remain undisclosed in the forecast. Applicants should expect a cooperative agreement structure, which indicates a substantial level of federal involvement in the implementation and monitoring of the funded project. Eligibility for the PCSS-SUD Treatment program is restricted to domestic public and private nonprofit entities. This includes professional organizations that are covered under the Medication Access and Training Expansion (MATE) Act. The program’s national focus and lack of geographic restriction in eligibility imply that it is open to qualified applicants across all U.S. states and territories. This inclusivity supports SAMHSA’s objective of broadening access to quality SUD treatment services by fostering nationwide partnerships and capacity building across healthcare disciplines. At this time, detailed application instructions, required components, and evaluation criteria have not been provided. However, since the grant is forecasted with an estimated post date of March 3, 2026, prospective applicants should monitor Grants.gov and SAMHSA's funding announcements for updates. The estimated application due date and award notification timelines are not yet defined. Interested applicants are encouraged to reach out to the listed contact, Belinda Greenfield, for any preliminary inquiries. She can be reached at (240) 276-2545 or via email at [email protected]. As a forecasted opportunity, the PCSS-SUD Treatment grant represents an early engagement stage for interested applicants. Those considering applying should begin preparing by assessing their organizational readiness, identifying internal stakeholders, and aligning existing resources to the program’s aims. They should also register or confirm active registration in SAM.gov and Grants.gov in anticipation of the application window opening. The projected next cycle for this program is March 2027 based on typical annual recurrence patterns, with an internal check recommended for March 1, 2027.